ReviewJournal of experimental & clinical cancer research : CR2025
PIEZO2 in tumors: from mechanobiological switches to activity-targeted therapies.
Review in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of a novel ion channel-related gene signature to predict prognosis and immune response of gastric cancer.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mechanosensitive ion channel PIEZO2 translates microenvironmental forces into Ca²⁺-dependent signals that shape tumor behavior. Across cancers, PIEZO2 exhibits context-dependent roles, with evidence for both pro- and anti-tumor functions, depending on tissue type, molecular subtype, disease stage, and stromal context. This review synthesizes emerging insights into the multifaceted roles of PIEZO2 in cancer biology, summarize clinical correlations, highlight areas with concordant directionality (e.g., colorectal cancer, medulloblastoma) versus paradoxical findings (e.g., breast cancer across subtypes, gastric cancer by differentiation status), and provide a pragmatic framework for precision, context aware targeting. While PIEZO2 remains attractive for combination strategies (anti-angiogenesis, barrier modulation, dormancy escape, radio/chemo sensitization) and cancer pain interfaces, the field lacks truly PIEZO2 selective small molecule modulators. We propose feasible future priorities encompassing both pharmacologic and non-pharmacologic strategies to accelerate translational applications.Graphical Abstract
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.